NICE nod for Sotyktu in psoriasis

US drug major Bristol Myers Squibb’s (NYSE: BMY) Sotyktu (deucravacitinib), a once-daily oral tablet, has been recommended for use on the National Health Service (NHS) in England as an option for treating certain adults with moderate to severe plaque psoriasis.

The National Institute for Health and Care Excellence’s (NICE) recommendation means that Sotyktu will be available to these patients if their psoriasis area and severity index is 10 or more, and the dermatology life quality index is more than 10, and if the condition has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated.

"Today’s announcement marks another step forward for people with psoriasis"This recommendation from the NICE follows receipt of marketing authorization in Great Britain last month for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.